Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Core One Labs Inc
(OP:
CLABF
)
0.1119
+0.0070 (+6.67%)
Streaming Delayed Price
Updated: 1:30 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Core One Labs Inc
< Previous
1
2
Next >
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
December 08, 2023
Via
ACCESSWIRE
Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
December 01, 2023
Via
ACCESSWIRE
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
August 04, 2023
Via
ACCESSWIRE
Core One Labs' Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT
September 02, 2022
Via
ACCESSWIRE
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
August 01, 2023
Via
ACCESSWIRE
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
July 28, 2023
Via
ACCESSWIRE
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
July 24, 2023
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal...
Via
Benzinga
Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds
July 24, 2023
GMP Drug Inc., a wholly-owned subsidiary of Core One Labs Inc. (OTCQB: CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN: A3CSSU) has entered into a non-binding letter of intent with Zollaris Laboratories...
Via
Benzinga
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
July 11, 2023
Via
ACCESSWIRE
Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
July 07, 2023
Via
ACCESSWIRE
Core One in Talks with Multiple Companies to Supply Psilocybin
May 05, 2023
Via
ACCESSWIRE
Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy
May 01, 2023
Via
ACCESSWIRE
Core One's Awakened Lays The Groundwork For The Large-Scale Production Of Psychedelic Compounds With Synthetic Production Of Psilocin
April 24, 2023
Core One Labs Inc. (OTCQB: CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN:A3CSSU) announced that its wholly-owned subsidiary, Awakened Biosciences Inc.
Via
Benzinga
Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility
April 21, 2023
Via
ACCESSWIRE
Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer's Begin
January 26, 2023
Core One Labs' Akome Partners To Study Next-Gen Psychedelics
Via
Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
January 25, 2023
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?
Via
Benzinga
Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases
January 24, 2023
Via
ACCESSWIRE
Here Are The Latest Psychedelics Partnerships From Production & Supply Chain To Community Action
January 21, 2023
Let’s do a quick tour of some of the latest announcements made by psychedelics companies over the past week. We promise you’ll be informed in less time than it takes to brew your coffee. New,...
Via
Benzinga
Core One Labs' Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers
January 13, 2023
Via
ACCESSWIRE
Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More
December 28, 2022
Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries
Via
Benzinga
Psychedelic Mushrooms Soon To Be Commercially Produced And Sold In Canada
December 21, 2022
After a successful commercial production trial, life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) is set to begin commercial production of its clinical-grade psilocybin at a Good...
Via
Benzinga
Core One Labs’ Prepares for Commercial Production of API-Grade Psilocybin; Plans Initial Production Run at GMP Facility in January
November 18, 2022
Via
ACCESSWIRE
Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities
October 21, 2022
Via
ACCESSWIRE
European University to Fund Core One Labs' Akome Advanced Neurogenesis Stimulation Studies
October 14, 2022
Via
ACCESSWIRE
Core One Labs Nearing GMP Production as Canada’s Province of Alberta Announces Game Changing Legislation
October 07, 2022
Via
ACCESSWIRE
Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
September 30, 2022
Via
ACCESSWIRE
Psychedelics Developer & Mass-Scale Manufacturer Will Deliver Novel Magic Mushroom Products
September 26, 2022
Life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) signed a Letter of Intent with GMP-certified manufacturer Medelys Laboratories International Inc. for the manufacturing of its...
Via
Benzinga
Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds
September 23, 2022
Via
ACCESSWIRE
Core One Labs' Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
September 16, 2022
Via
ACCESSWIRE
New Biosynthetic Psilocybin Hits The Psychedelics Market, Available For Research And Clinical Trials
September 02, 2022
With psilocybin among the favorites within psychedelics,
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.